Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 2/20 | 0.64 |
| ▸ | GABRD | O14764 | 2/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.64 |
| ▸ | GABRE | P78334 | 2/20 | 0.64 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.64 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.64 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080781 | 0.88 | MAPT (0.78) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL9563516 | 0.85 | SMN1; SMN2 (0.74) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL18054756 | 0.80 | MAPT (0.70) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL9686366 | 0.79 | SMN1; SMN2 (0.65) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL11061295 | 0.78 | GABRP (1.00) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL9686196 | 0.77 | MAPT (0.61) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL7324248 | 0.76 | GABRP (0.75) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL3481659 | 0.75 | MAPT (0.59) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL11312506 | 0.74 | GABRP (0.62) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL9821773 | 0.73 | L3MBTL1 (0.58) | MAPTSMN1; SMN2CYP1A2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440443-B2 | Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4520828-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | The Schepens Eye Research Institute, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| EP-3541408-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | SCHEPENS EYE RES INST (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118325965-A | Application of ZmCPK protein or coding gene thereof in regulation and control of plant cold resistance | 中国农业大学 | 2024-07-12 | — | — | CN | disclosed |
| US-20240175022-A1 | RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal Transition | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-05-30 | — | — | US | disclosed |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-08-29 | — | — | US | disclosed |
| US-9446048-B2 | Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446048-B2 | Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446048-B2 | Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2685985-B1 | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBF AND RUNX1 PROTEINS | US HEALTH (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2685985-B1 | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBF AND RUNX1 PROTEINS | US HEALTH (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2685985-A1 | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBF AND RUNX1 PROTEINS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140004082-A1 | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFBETA AND RUNX1 PROTEINS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-01-02 | — | — | US | disclosed |
| WO-2012125787-A1 | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFβ AND RUNX1 PROTEINS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125787-A1 | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFβ AND RUNX1 PROTEINS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2012-09-20 | — | — | WO | disclosed |
| EP-0429868-A2 | Use of a benzodiazepin- and a phenylpyrrylketone derivative in retroviral infection | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240175022-A1 | RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal Transition | RUNX1, CXCL12, MITF | MAPT 2892/4885SMN1; SMN2 2996/4885CYP1A2 4809/4885 |
| US-20140004082-A1 | METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFBETA AND RUNX1 PROTEINS | CBFB, RUNX1, MCL1 | MAPT 3148/4885SMN1; SMN2 3033/4885CYP1A2 4434/4885 |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | MAPT 3713/4885SMN1; SMN2 1532/4885CYP1A2 3030/4885 |
| US-12440443-B2 | Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver | RUNX1, CBFB, IKZF1 | MAPT 1297/4885SMN1; SMN2 4291/4885CYP1A2 2875/4885 |
| US-11739326-B2 | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition | RUNX1, CXCL12, MITF | MAPT 2925/4885SMN1; SMN2 2992/4885CYP1A2 4819/4885 |
| US-20230277454-A1 | NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | RUNX1, CBFB, IKZF1 | MAPT 1318/4885SMN1; SMN2 4240/4885CYP1A2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.